{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"description":"The maximum tolerated dose was defined as the highest dose level at which no more than 1 of 6 participants experiences a DLT within the first 28-day cycle.\n\nDLTs were defined as:\n\n* Grade 4 neutropenia or thrombocytopenia\n* Febrile neutropenia\n* Grade 3 or 4 nausea, vomiting or diarrhea despite optimal symptomatic treatment\n* Serum transaminase \\> 20 \\* upper limit of normal (ULN)\n* Serum transaminase \\> 5 \\* ULN for \\>= 7 days\n* Delay of the start of cycle 2 by \\>7 days due to pomalidomide-related adverse event","groups":[{"description":"Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"OG000","title":"Phase 1: 2 mg Pomalidomide"},{"description":"Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"OG001","title":"Phase 1: 3 mg Pomalidomide"},{"description":"Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"OG002","title":"Phase 1: 4 mg Pomalidomide"},{"description":"Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.","id":"OG003","title":"Phase 1: 5 mg Pomalidomide"}],"paramType":"NUMBER","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"Up to Day 28 (Cycle 1)","title":"Phase 1: Participants With Dose-Limiting Toxicities (DLT) in Cycle 1","type":"PRIMARY","unitOfMeasure":"participants"}